Currently, Drug Counterfeiting is the biggest challenge facing the pharmaceutical industry. They are encountering this threat due to high market demand for the drugs and their profit margin. The lack of data transparency and traceability also lured criminals into the counterfeiting of drugs which, is impacting people’s health and put their life in danger. Through the drug supply chain, a substantial portion of counterfeit drugs are injected and distributed through the healthcare supply chain network, so the supply chain plays a vital role in drug distribution and impacts patient lives. Through digitalization in the healthcare sector, Distributed Ledger Technology (DLT) provides a platform with ground-breaking results by providing a system for drug traceability with consideration of the critical requirements of transparency, privacy, and authenticity without involving any third party. In DLT, each distribution partner is registered to maintain transparency with the drug information. Real-time transfer of information about the change of ownership with date and time in the form of blocks gives visibility to all the partners in real time about the authenticity of drugs. This article will give information about the benefits of Distributed Ledger Technology to the pharmaceutical industry and the traceability of drugs from end-to-end of the pharmaceutical supply chain.

Pharmaceutical drug traceability is a regulatory compliance adopted by most nations in the world. A comprehensive analysis was carried out to explain the benefits of adopting enterprise system for pharmaceutical drug traceability. Counterfeit drugs are medicines that are fake and have been produced using incorrect potency, or incorrect ingredients used to manufacture these drugs. Solving the drug counterfeiting problems by identifying the most effective and innovative technologies for protecting people's health is of essence these days for the world. Drug serialization is essential concept for drug traceability in the pharmaceutical supply chain. Blockchain is the latest stringent technology that makes drug distribution more secure in the supply chain. The blockchain-based drug traceability is a distributed shared data platform that shares information that is irreversible, reliable, responsible, and transparent in the PSC. Blockchain uses two powerful module, Hyperledger Fabric and Besu to satisfy important criteria for medication traceability, such as privacy, trust, transparency, security, authorization and authentication, and scalability. Researchers in Health informatics can use blockchain designs as a useful road map to develop and implement end-to-end pharmaceutical drug traceability in the supply chain to prevent drug counterfeiting. Industrial IoT is also a key component for the pharmaceutical industry. IoT systems in pharmaceutical drug traceability can be beneficial as they are based on automation and computational methodologies.

The growing complexity of the operating environment urges pharmaceutical innovation. This essay addresses the need for the integration of advanced technologies in the pharmaceutical supply chain. It justifies the value proposition and presents a concrete use case for the integration of deep learning insights to make data-driven decisions. The supply chain has always been a priority for the pharmaceutical industry; research and development recognizes companies' increasing investment in big data strategies, with plans for a CAGR in big data tool adoption. The work presented herein has a preliminary explorative character to recuperate and integrate evidence from partly overlooked practical experience and know-how. The practical relevance of the essay is directed toward practitioners in pharmaceutical production, supply chain management, logistics, and regulatory agencies. The literature has shown a long-term concern for enhanced performance in the pharmaceutical supply chain network. This essay demonstrates the application of deep learning-driven insights to reveal non-evident flow dependencies. The main aim is to present a comprehensive insight into deep learning-driven decision support. The supply chain is portrayed in a holistic manner, seeking end-to-end visibility. Implications for public policy are discussed, such as data equity: many countries are protecting their populations and economic growth by building resilience and efficiency to ensure the capacity to move goods across supply chains. The implementation strategy is covered. The combined reduction of variability, efficiency as matured richness, reliability (on stochastic flows and their understanding through deep learning and data), and system noise (increased dampening through the inclusiveness of all stakeholders) results in increased responsiveness of supply chains for pharmaceutical products. Future work involves the integration of external data, closing the loop between planning and its application in reality.